Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer
- 1 March 2005
- journal article
- case report
- Published by Elsevier BV in Gynecologic Oncology
- Vol. 96 (3), 902-905
- https://doi.org/10.1016/j.ygyno.2004.12.001
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Remaining controversies in the upfront management of advanced ovarian cancerInternational Journal of Gynecologic Cancer, 2004
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Evaluation of the antiangiogenic effect of Taxol in a human epithelial ovarian carcinoma cell lineCancer Chemotherapy and Pharmacology, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Angiogenesis in epithelian ovarian cancerMolecular Pathology, 2002